trending Market Intelligence /marketintelligence/en/news-insights/trending/GGJsaNn9DNkQHfwk2jei0A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

McConnell on insurer payments; Gilead, GSK considering United Therapeutics buy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

McConnell on insurer payments; Gilead, GSK considering United Therapeutics buy

* Senate Majority Leader Mitch McConnell, R-Ky., is willing to consider bipartisan effort to continue cost-sharing reduction subsidies, or CSRs, for insurers, Bloomberg News reported. CSRs are payments the government makes to insurers to keep costs low for low-income or intensive-care patients and to prevent such costs from ballooning for companies.

M&A and capital markets

* Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for biotechnology company United Therapeutics Corp., the Evening Standard reported, citing anonymous sources. According to the sources, United could be worth as much as $200 per share in a sale, making the purchase price about $8.7 billion.

Drug and product pipeline

* The U.S. Food and Drug Administration granted tentative approval to Perrigo Company plc's generic version of Mirvaso to treat persistent facial redness of rosacea, a common skin disease.

Operational activity

* In an interview with the Financial Times, CEO Emma Walmsley shared her plans to improve GlaxoSmithKline plc's return on research and development by pursuing products of high commercial value to the drug maker. Walmsley also intends to overhaul the company's incentive structure to improve accountability and drive performance.

* A U.S. court in Brooklyn found former drug company executive Martin Shkreli guilty of defrauding investors in hedge funds MSMB Capital Management LLC and MSMB Healthcare Ltd., and pharmaceutical company Retrophin, Inc.

* The U.S. Drug Enforcement Administration proposed a 20% reduction in the production quotas of certain opioid painkillers in 2018. "Physicians, pharmacists, and patients must recognize the inherent risks of these powerful medications, especially for long-term use," said Chuck Rosenberg, acting administrator.

The day ahead

Early morning futures indicators pointed to a higher opening for the U.S. market.

In Asia, the Hang Seng was up 0.46% to 27690.36. The Nikkei 225 rose 0.52% to 20,055.89.

In Europe as of midday, the FTSE 100 was up 0.14% to 7,522.26, and the Euronext 100 slid 0.04% to 1,011.71.

Now featured on S&P Global Market Intelligence:

* Allergan's Teva ties may have pushed both stocks down, analyst says: Allergan plc had a steady second quarter with several products beating sales expectations, but executive comments about Teva Pharmaceutical Industries Ltd. may have hurt both company's stocks, an analyst speculated.

* J&J research exec talks changing HIV treatments, long-term dosing in the future: With a recent batch of data in hand on experimental HIV drugs, Brian Woodfall, global head of late development for infectious diseases and vaccines for Johnson & Johnson's Janssen unit, spoke with S&P Global Market Intelligence about the changing landscape of HIV treatment.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.